Colon Cancer Biomarkers
What Patients Need to Know
RAS mutation status (KRAS/NRAS) and mismatch repair testing (MSI-H/dMMR) must be completed before any treatment begins — they directly determine which drugs can and cannot help.
Reviewed by XpertPatient Medical Advisory · Updated June 2026 · Sources: NCI · ACS · ASCO · NIH/PMC
Why This Matters
Biomarker testing before colon cancer treatment
In colon cancer, certain tests must be done before treatment starts — not because they’re optional, but because the results directly change which medicines will and won’t help you.
Using the wrong drug on the wrong tumor won’t just fail — it exposes you to side effects for no benefit. Your biomarker results protect you from that.
The Biomarkers Your Doctor Tests
🔍 Do you have a mutation that blocks certain drugs from working?
If your tumor has a RAS mutation (found in about 50% of colon cancers), drugs like cetuximab and panitumumab will NOT work — they should not be used. Knowing this upfront protects you from unnecessary treatment.
🔍 Does your cancer respond to immunotherapy?
About 15% of colon cancers are MSI-H. This is very important: MSI-H colon cancer responds exceptionally well to immunotherapy with pembrolizumab. In fact, pembrolizumab is now approved as a first-line treatment for MSI-H metastatic colon cancer.
🔍 Is there a specific mutation linked to more aggressive disease?
BRAF V600E is found in about 10% of colon cancers and signals more aggressive behavior. There’s now a targeted drug combination — encorafenib plus cetuximab — that works specifically against BRAF-mutated colon cancer.
Common Questions
Colon Cancer Biomarkers — Frequently Asked Questions
❓ What does RAS wild-type mean?
‘Wild-type’ means your tumor does NOT have a RAS mutation. This is actually good news — it means you’re eligible for EGFR-targeting drugs like cetuximab or panitumumab, which can be added to chemotherapy for better results.
❓ What is MSI-H colorectal cancer?
MSI-H (microsatellite instability-high) means the cancer has a defect in its DNA repair system. These tumors collect lots of mutations, which makes them very visible to the immune system. That’s why immunotherapy works so well — your immune system can now recognize and attack the cancer.
❓ Should I get comprehensive genomic profiling for colon cancer?
Yes, especially for metastatic disease. Beyond RAS, BRAF, and MSI, there are rarer mutations — like HER2 amplification and NTRK fusions — that can be treated with targeted drugs. A comprehensive panel finds all of them at once.
❓ Can I request biomarker testing if my doctor hasn’t ordered it?
Absolutely. You have every right to ask. Tell your doctor: ‘I’d like comprehensive biomarker testing, including RAS, BRAF, MSI/dMMR, and HER2, before we start treatment.’ Most guidelines recommend this, and most insurance plans cover it.
Know Your Biomarkers. Own Your Journey.
Free, survivor-led cancer education — built for newly diagnosed patients.
Visit the Colon Cancer Center → Full Biomarkers Guide →
